Mouse CD30L ELISA Kit (DEIA760)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
serum, plasma, tissues homogenates, other biological fluids
Species Reactivity
Mouse
Intended Use
The ELISA kit is a sandwich enzyme immunoassay for the in vitro quantitative measurement of Mouse CD30L in serum, plasma, tissue homogenates and other biological fluids.
Contents of Kit
1. Pre-Coated 96-well strip plate: 1
2. Plate sealer for 96 wells: 4
3. Standard: 2
4. Standard Diluent: 1 x 20 mL
5. Detection Reagent A: 1 x 120 μL
6. Assay Diluent A (2X): 1 x 6 mL10.
7. Detection Reagent B: 1 x 120 μL
8. Assay Diluent B (2X): 1 x 6 mL
9. TMB Substrate: 1 x 9 mL
10. Stop Solution: 1 x 6 mL
11. Wash Buffer (30X): 1 x 20 mL
12. Instruction manual: 1
Storage
Store the reagents at 2-8°C until expiration date. For more detailed information, please download the following document on our website.
Detection Range
0.156-10 ng/mL
Detection Limit
0.032 ng/mL
Sensitivity
0.032 ng/mL

Citations


Have you cited DEIA760 in a publication? Let us know and earn a reward for your research.

Related Products


CD30 ELISA KIT (DEIA6163)

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


MAGEC2 is a sensitive and novel marker for seminoma: a tissue microarray analysis of 325 testicular germ cell tumors

MODERN PATHOLOGY

Authors: Bode, Peter K.; Barghorn, Andre; Fritzsche, Florian R.; Riener, Marc-Oliver; Kristiansen, Glen; Knuth, Alexander; Moch, Holger

Melanoma-associated gene C2 (MAGEC2) is a recently identified cancer testis antigen expressed in normal testicular and placental tissue. It has been detected in some human carcinomas, but its expression in primary testicular germ cell tumors is unknown. Immunohistochemistry was used to study MAGEC2 protein in 325 primary testicular germ cell tumors, including 94 mixed germ cell tumors. Seminomatous and non-seminomatous components were separately arranged and evaluated on tissue microarrays. MAGEC2 expression was compared with POU5F1 (OCT3/4), SOX2, SOX17, KIT and TNFRSF8 (CD30). The mouse monoclonal anti-MAGEC2 antibody (clone LX-CT10.5) revealed a nuclear MAGEC2 expression with little or no background staining. MAGEC2 expression was found in 238 of 254 seminomas (94%), but not in embryonal carcinomas (n = 89). POU5F1 (OCT3/4) was positive in 97% of seminomas and all embryonal carcinomas. In contrast, KIT was positive in 94% of seminoma but also in 8% of embryonal carcinomas. TNFRSF8 (CD30) and SOX2 were negative in seminoma and positive in embryonal carcinoma (96 and 90%, respectively). SOX17 was positive in 94% of seminoma and negative in embryonal carcinoma. We conclude that MAGEC2 allows a reliable distinction of seminoma from embryonal carcinomas. Therefore, MAGEC2 represents an additional tool for the differential diagnosis of testicular germ cell tumors. Modern Pathology (2011) 24, 829-835; doi:10.1038/modpathol.2011.6; published online 4 March 2011

CD30 Expression by B and T Cells A Frequent Finding in Angioimmunoblastic T-Cell Lymphoma and Peripheral T-Cell Lymphoma-Not Otherwise Specified

AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Authors: Onaindia, Arantza; Martinez, Nerea; Montes-Moreno, Santiago; Almaraz, Carmen; Rodriguez-Pinilla, Socorro M.; Cereceda, Laura; Revert, Jose B.; Ortega, Cesar; Tardio, Antoni; Gonzalez, Lucia; Garcia, Sonia; Camacho, Francisca I.; Gonzalez-Vela, Carmen; Piris, Miguel A.

CD30 expression in peripheral T-cell lymphoma (PTCL) and angioimmunoblastic T-cell lymphoma (AITL) is currently of great interest because therapy targeting CD30 is of clinical benefit, but the clinical and therapeutic relevance of CD30 expression in these neoplasms still remains uncertain. The aim of this study was to better quantify CD30 expression in AITL and PTCL-not otherwise specified (NOS). The secondary objective was to determine whether CD30(+) cells exhibit a B-cell or a T-cell phenotype. Gene expression profiling was studied in a series of 37 PTCL cases demonstrating a continuous spectrum of TNFRSF8 expression. This prompted us to study CD30 immunohistochemical (IHC) expression and mRNA levels by reverse transcription polymerase chain reaction (RT-PCR) in a different series of 51 cases (43 AITLs and 8 PTCL-NOSs) in routine samples. Double stainings with PAX5/CD30, CD3/CD30, and LEF1/CD30 were performed to study the phenotype of CD30(+) cells. Most (90%) of the cases showed some level of CD30 expression by IHC (1% to 95%); these levels were high (> 50% of tumoral cells) in 14% of cases. CD30 expression was not detected in 10% of the cases. Quantitative RT-PCR results largely confirmed these findings, demonstrating a moderately strong correlation between global CD30 IHC and mRNA levels (r=0.65, P=1.75e-7). Forty-four of the positive cases (98%) contained CD30-positive B cells (PAX5), whereas atypical CD30-positive T cells were detected in 42 cases (93%). In conclusion, our data show that most AITL and PTCL-NOS cases express CD30, exhibiting very variable levels of CD30 expression that may be measured by IHC or RT-PCR techniques.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket